Based on the company's experience in cell drug development and its portfolio of 33 patents, it has mastered high-standard clinical-grade cell banks and the various technologies for exosome mass production, purification, and characterization. This enables the large-scale and efficient manufacture of high-purity exosomes for specific applications with consistent quality.
The exosomes derived from the developed umbilical cord mesenchymal stem cells have received International Nomenclature of Cosmetic Ingredients (INCI) certification, and are included in the
international cosmetics and skincare ingredient list.
Our laboratory has established a fully automated exosome production system with a capacity of 100 liters.